[The pharmacoeconomics of testicular cancer in Ukraine].

An ever-growing cost of health care in Ukraine attest to the need for an optimum employment of resources in diagnosing and treating disorders of major public health significance, testicular carcinoma (TC) among their number. The authors consider it expedient to ascertain TC costs and design an analytical framework for the diagnostic and therapeutic options to be assessed properly. The following combination chemotherapy regimens were found to be associated with high response rates and acceptable longterm survival: BEP, PE programmes for primary treatment and PEI programme for recurrent or refractory TC.